SEC 13F Intelligence

Managers / Q2 2020 · view latest →

SECTORAL ASSET MANAGEMENT INC

CIK 0001274413 · 1010 SHERBROOKE ST., WEST, SUITE 1610, MONTREAL, A8, H3A 2R7 · 514 849 8777

Reported Value
$1.1B
Q2 2020
Positions
191
Filings on Record
30
2019–present window
Filed
Aug 13, 2020
original filing

Summary

Sectoral Asset Management Inc reported $1.1B in U.S.-listed holdings across 191 positions for Q2 2020.

Its largest position, Aprea Therapeutics, represents 3.3% of the portfolio.

Compared with Q1 2020, the fund opened 132 new positions and exited 6.

Portfolio Metrics

Turnover
+10.3%
vs prior filed quarter
Top-10 Concentration
+23.6%
share of reported value
Largest Position
+3.3%
Aprea Therapeutics
New / Exited
132 / 6
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $736MQ4 ’18Q1 ’19: $831MQ2 ’19: $836MQ3 ’19: $580MQ4 ’19: $670MQ4 ’19Q1 ’20: $521MQ2 ’20: $1.1BQ3 ’20: $1.2BQ4 ’20: $1.4BQ4 ’20Q1 ’21: $1.3BQ2 ’21: $1.2BQ3 ’21: $1.2BQ4 ’21: $664MQ4 ’21Q1 ’22: $563MQ2 ’22: $496MQ3 ’22: $508MQ4 ’22: $517MQ4 ’22Q1 ’23: $520MQ2 ’23: $600MQ3 ’23: $514MQ4 ’23: $232MQ4 ’23Q1 ’24: $254MQ2 ’24: $246MQ3 ’24: $169MQ4 ’24: $150MQ4 ’24Q1 ’25: $128MQ2 ’25: $151MQ3 ’25: $162MQ4 ’25: $125MQ4 ’25Q1 ’26: $121Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 85.5%Other: 13.7%ADR: 0.8%
  • Common Stock · 85.5% · $932M
  • Other · 13.7% · $149M
  • ADR · 0.8% · $9M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2020 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
CNCCENTENE CORP DELNEW+401.2K401.2K+$25M$25M
ARNAEURARENA PHARMACEUTICALNEW+362.9K362.9K+$23M$23M
2655787DBLUEPRINT MEDICINESNEW+290.6K290.6K+$23M$23M
DC4DEXCOM INCNEW+44.2K44.2K+$18M$18M
HCATHEALTH CATALYST INNEW+563.0K563.0K+$16M$16M
ARVNARVINAS INCNEW+467.0K467.0K+$16M$16M
MOHMOLINA HEALTHCARENEW+83.5K83.5K+$15M$15M
ALXNALEXION PHARM INCNEW+125.8K125.8K+$14M$14M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2020

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1APREA THERAPEUTICSCOM3.26%$36M915.7K
2HRCHILL-ROM HLDS INChistory →COM2.52%$27M249.7K
3PTCTPTC THERAPEUTICS Ihistory →COM2.43%$26M520.7K
4AM6AMICUS THERAPEUTICShistory →COM2.42%$26M1.75M
5CNCCENTENE CORP DELhistory →COM2.34%$25M401.2K
6APLSUSDAPELLIS PHARMACEUTIChistory →COM2.30%$25M768.6K
7ARNAEURARENA PHARMACEUTICALhistory →COM2.10%$23M362.9K
8EX9EXELIXIS INChistory →COM2.09%$23M957.4K
92655787DBLUEPRINT MEDICINEShistory →COM2.08%$23M290.6K
10TDOCTELADOC HEALTHhistory →COM2.07%$23M118.3K
11SILKUSDSILK ROAD MEDICALhistory →COM2.01%$22M522.2K
12PPD INCCOM1.90%$21M772.4K
13TFXTELEFLEX INChistory →COM1.89%$21M56.4K
14CSIIEURCARDIOVASCULAR SYShistory →COM1.88%$21M650.6K
15BSXBOSTON SCIENTIFIChistory →COM1.85%$20M574.6K
16TNDMTANDEM DIABETES CAREhistory →COM1.79%$19M197.0K
17IMMUIMMUNOMEDICS INChistory →COM1.73%$19M531.8K
18ATRCATRICURE INChistory →COM1.71%$19M414.6K
19TURNING POINT THERAPCOM1.69%$18M284.5K
20RCMEURR1 RCM INChistory →COM1.68%$18M1.64M
21HMSYHMS HOLDINGS CORPhistory →COM1.67%$18M561.6K
22DC4DEXCOM INChistory →COM1.65%$18M44.2K
23TRHCEURTABULA RASA HEALTHhistory →COM1.58%$17M314.9K
24ACADACADIA PHARMACEUTCLShistory →COM1.52%$17M342.7K
25HCATHEALTH CATALYST INhistory →COM1.51%$16M563.0K
26BMRNBIOMARIN PHARMAC INChistory →COM1.49%$16M131.6K
27CHNGUSDCHANGE HEALTHCARE INhistory →COM1.47%$16M1.43M
28ARVNARVINAS INChistory →COM1.44%$16M467.0K
29ASSEMBLY BIOSCIENCESCOM1.41%$15M657.1K
30MOHMOLINA HEALTHCAREhistory →COM1.36%$15M83.5K
31INCYINCYTE CORPORATIONhistory →COM1.34%$15M140.4K
32GBTUSDGLOBAL BLOOD THERAhistory →COM1.33%$14M229.3K
33MRTXEURMIRATI THERAPEUTICShistory →COM1.31%$14M125.3K
34ALXNALEXION PHARM INChistory →COM1.30%$14M125.8K
35SRPTSAREPTA THERAPEUTICShistory →COM1.29%$14M87.8K
36RMERESMED INChistory →COM1.27%$14M72.3K
37SGENUSDSEATTLE GENETICS INChistory →COM1.27%$14M81.6K
38IRTCIRHYTHM TECHNOLOGIEShistory →COM1.23%$13M115.9K
39DCPHEURDECIPHERA PHARMACEUThistory →COM1.23%$13M224.4K
40BMYBRISTOL MYERS SQUIBBhistory →COM1.21%$13M225.0K
41EVHEVOLENT HEALTH INChistory →COM1.19%$13M1.82M
42COLLCOLLEGIUM PHARMACEUThistory →COM1.05%$11M654.5K
43UNIQURE N.V.SHS1.04%$11M251.2K
44REGNREGENERON PHARMCTCLShistory →COM1.03%$11M18.0K
45FORMA THERAPEUTICSCOM1.01%$11M237.2K
46UNHUNITEDHEALTH GRP INChistory →COM0.99%$11M36.5K
47GENERATION BIO COCOM0.99%$11M511.3K
48ABBVABBVIE INChistory →COM0.94%$10M104.8K
49RGENREPLIGEN CORPhistory →COM0.93%$10M82.4K
50PRAHPRA HEALTH SCIENCECOM0.89%$10M99.7K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$121M77May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$125M74Feb 9, 202613F-HRchanges · EDGAR ↗
Q3 2025$162M82Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$151M94Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$128M84May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$150M86Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$169M90Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$246M97Aug 13, 202413F-HRchanges · EDGAR ↗
Q1 2024$254M92May 14, 202413F-HRchanges · EDGAR ↗
Q4 2023$232M104Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$514M123Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$600M121Aug 11, 202313F-HRchanges · EDGAR ↗
Q1 2023$520M118May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022$517M120Feb 10, 202313F-HRchanges · EDGAR ↗
Q3 2022$508M109Nov 10, 202213F-HRchanges · EDGAR ↗
Q2 2022$496M112Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$563M106May 10, 202213F-HRchanges · EDGAR ↗
Q4 2021$664M108Feb 11, 202213F-HRchanges · EDGAR ↗
Q3 2021$1.2B127Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$1.2B127Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$1.3B113May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$1.4B97Feb 12, 202113F-HRchanges · EDGAR ↗
Q3 2020$1.2B88Nov 13, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.1B191Aug 13, 202013F-HRchanges · EDGAR ↗
Q1 2020$521M65May 13, 202013F-HRchanges · EDGAR ↗
Q4 2019$670M65Feb 12, 202013F-HRchanges · EDGAR ↗
Q3 2019$580M63Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$836M92Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$831M106May 14, 201913F-HRchanges · EDGAR ↗
Q4 2018$736M104Feb 12, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.